Sense Biodetection has raised $15.8m in a series A round co-led by Cambridge Innovation Capital and Earlybird to produce a diagnostic test for infectious diseases.

Sense Biodetection, a UK-based molecular diagnostic tests developer, raised £12.3m ($15.8m) in a series A round on Tuesday co-led by university-affiliated patient capital fund Cambridge Innovation Capital (CIC) and VC firm Earlybird.
Sense Biodetection is creating a range of instrument-free, point-of-care molecular diagnostic tests that it will initially use to detect infectious diseases such as influenza. Due to their nature of being single us and not requiring instruments, Sense’s tests could be deployed in any setting.
The series…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in